{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:16:38Z","timestamp":1787987798312,"version":"build-2784847793"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NSFC cultivation project of Jining Medical University","award":["JYP2019KJ10"],"award-info":[{"award-number":["JYP2019KJ10"]}]},{"name":"Medical and Health Science and Technology Development Project of Shandong Province","award":["2019WS357"],"award-info":[{"award-number":["2019WS357"]}]},{"name":"open project of Shanxi Provincial Key Laboratory of Forensic Science, China","award":["SFM2019002"],"award-info":[{"award-number":["SFM2019002"]}]},{"name":"Student Innovation Training Program Project of Shandong Province","award":["S202010443043"],"award-info":[{"award-number":["S202010443043"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>CYP4B1 belongs to the mammalian CYP4 enzyme family and is predominantly expressed in the lungs of humans. It is responsible for the oxidative metabolism of a wide range of endogenous compounds and xenobiotics. In this study, using data from The Cancer Genome Atlas (TCGA) project and the Gene Expression Omnibus (GEO) database, a secondary analysis was performed to explore the expression profile of <jats:italic>CYP4B1<\/jats:italic>, as well as its prognostic value in patients with lung adenocarcinoma (LUAD). Based on the obtained results, a significantly decreased <jats:italic>CYP4B1<\/jats:italic> expression was discovered in patients with LUAD when compared with their normal counterparts (<jats:italic>p<\/jats:italic>&lt;0.05), and was linked to age younger than 65 years (<jats:italic>p<\/jats:italic> = 0.0041), history of pharmaceutical (<jats:italic>p<\/jats:italic> = 0.0127) and radiation (<jats:italic>p<\/jats:italic> = 0.0340) therapy, mutations in <jats:italic>KRAS\/EGFR\/ALK<\/jats:italic> (<jats:italic>p<\/jats:italic> = 0.0239), and living status of dead (<jats:italic>p<\/jats:italic> = 0.0026). Survival analysis indicated that the low <jats:italic>CYP4B1<\/jats:italic> expression was an independent prognostic indicator of shorter survival in terms of overall survival (OS) and recurrence-free survival (RFS) in patients with LUAD. The copy number alterations (CNAs) and sites of cg23440155 and cg23414387 hypermethylation might contribute to the decreased <jats:italic>CYP4B1<\/jats:italic> expression. Gene set enrichment analysis (GSEA) suggested that <jats:italic>CYP4B1<\/jats:italic> might act as an oncogene in LUAD by preventing biological metabolism pathways of exogenous and endogenous compounds and enhancing DNA replication and cell cycle activities. In conclusion, <jats:italic>CYP4B1<\/jats:italic> expression may serve as a valuable independent prognostic biomarker and a potential therapeutic target in patients with LUAD.<\/jats:p>","DOI":"10.1371\/journal.pone.0247020","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T22:02:08Z","timestamp":1613512928000},"page":"e0247020","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma"],"prefix":"10.1371","volume":"16","author":[{"given":"Xiaoling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6032-5638","authenticated-orcid":true,"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"8","key":"pone.0247020.ref001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"J Ferly","year":"2019","journal-title":"Int J Cancer"},{"key":"pone.0247020.ref002","volume-title":"DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles & Practice of Oncology","author":"VT Devita","year":"2015","edition":"1"},{"issue":"1","key":"pone.0247020.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2014an update","volume":"25","author":"LA Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"pone.0247020.ref004","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.21037\/jtd.2017.06.20","article-title":"Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy","volume":"9","author":"R Chalela","year":"2017","journal-title":"J Thorac Dis"},{"issue":"2","key":"pone.0247020.ref005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41419-017-0063-y","article-title":"Cell death-based treatment of lung adenocarcinoma","volume":"9","author":"TV Denisenko","year":"2018","journal-title":"Cell Death Dis"},{"key":"pone.0247020.ref006","unstructured":"Cancer Facts & Figures 2020. American Cancer Society. 2020. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html"},{"key":"pone.0247020.ref007","first-page":"81","article-title":"Association of cytochrome P450 with cancer induced by","volume":"2","author":"A Adhikari","year":"2015","journal-title":"Betel quid"},{"issue":"1","key":"pone.0247020.ref008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/BJ20140813","article-title":"Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol","volume":"465","author":"C Wiek","year":"2015","journal-title":"Biochem J"},{"issue":"4","key":"pone.0247020.ref009","first-page":"1085","article-title":"Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors","volume":"54","author":"M Czerwinski","year":"1994","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0247020.ref010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1006\/bbrc.2000.3740","article-title":"CYP4B1 is a possible risk factor for bladder cancer in humans","volume":"277","author":"S Imaoka","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0247020.ref011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1012526406741","article-title":"The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue","volume":"70","author":"M Iscan","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pone.0247020.ref012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.surg.2016.04.056","article-title":"Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis","volume":"161","author":"TD Murtha","year":"2017","journal-title":"Surgery"},{"issue":"4","key":"pone.0247020.ref013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/apm.12939","article-title":"Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder","volume":"127","author":"JT Lin","year":"2019","journal-title":"APMIS"},{"issue":"3\u20134","key":"pone.0247020.ref014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.prostaglandins.2007.05.001","article-title":"Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1","volume":"84","author":"F Seta","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"pone.0247020.ref015","volume-title":"AJCC Cancer Staging Manual","author":"MB Amin","year":"2018","edition":"8"},{"issue":"D1","key":"pone.0247020.ref016","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"SV Vasaikar","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"pone.0247020.ref017","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"ZF Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"pone.0247020.ref018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/03602530600688503","article-title":"CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism","volume":"38","author":"BR Baer","year":"2006","journal-title":"Drug Metab Rev"},{"issue":"1","key":"pone.0247020.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-200401000-00001","article-title":"Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants","volume":"14","author":"DR Nelson","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"9","key":"pone.0247020.ref020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1089\/hum.1998.9.9-1261","article-title":"New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene\/4-ipomeanol","volume":"9","author":"NG Rainov","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"1","key":"pone.0247020.ref021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/108076804772745473","article-title":"Retinoic acid induces corneal epithelial CYP4B1 gene expression and stimulates the synthesis of inflammatory 12-hydroxyeicosanoids","volume":"20","author":"S Ashkar","year":"2004","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"pone.0247020.ref022","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/jcb.20018","article-title":"Promoter activity and regulation of the corneal CYP4B1 gene by hypoxia","volume":"91","author":"V Mastyugin","year":"2004","journal-title":"J Cell Biochem"},{"issue":"5","key":"pone.0247020.ref023","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00008571-200207000-00004","article-title":"Genetic polymorphism of the human cytochrome P450 CYP4B1: evidence for a non-functional allelic variant","volume":"12","author":"JM Lo-Guidice","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"2","key":"pone.0247020.ref024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2133\/dmpk.19.114","article-title":"Human CYP4B1 gene in the japanese population analyzed by denaturing HPLC","volume":"19","author":"M Hiratsuka","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"pone.0247020.ref025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2133\/dmpk.DMPK-11-RG-046","article-title":"Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan","volume":"26","author":"Y Tamaki","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"pone.0247020.ref026","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jjco\/hyn081","article-title":"Possible relationship between the risk of Japanese bladder cancer cases and the CYP4B1 genotype","volume":"38","author":"T Sasaki","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"pone.0247020.ref027","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1007\/s13277-014-2284-3","article-title":"Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells","volume":"35","author":"GP Yu","year":"2014","journal-title":"Tumour Biol"},{"issue":"4","key":"pone.0247020.ref028","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1002\/jcb.27817","article-title":"Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway","volume":"120","author":"W Jian","year":"2019","journal-title":"J Cell Biochem"},{"issue":"10","key":"pone.0247020.ref029","first-page":"1806","article-title":"Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K\/Akt\/mTOR axis","volume":"7","author":"GP Yu","year":"2015","journal-title":"J Thorac Dis"},{"issue":"1","key":"pone.0247020.ref030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13277-011-0265-3","article-title":"PEBP4 gene expression and its significance in invasion and metastasis of non-small cell lung cancer","volume":"33","author":"GP Yu","year":"2012","journal-title":"Tumour Biol"},{"issue":"46","key":"pone.0247020.ref031","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1038\/onc.2017.253","article-title":"Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients","volume":"36","author":"Y Umeda","year":"2017","journal-title":"Oncogene"},{"key":"pone.0247020.ref032","doi-asserted-by":"crossref","first-page":"106155","DOI":"10.1016\/j.intimp.2019.106155","article-title":"Effects of ALOX5, IL6R and SFTPD gene polymorphisms on the risk of lung cancer: A case-control study in China","volume":"79","author":"XP Wei","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"pone.0247020.ref033","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/15412555.2012.676110","article-title":"Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population","volume":"9","author":"T Ishii","year":"2012","journal-title":"COPD"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T22:02:45Z","timestamp":1613512965000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247020"}},"subtitle":[],"editor":[{"given":"Hiromu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247020","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}